EMNC yields 200000000.00% · ABBV yields 3.06%● Live data
📍 EMNC pulled ahead of the other in Year 1
Combined, EMNC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EMNC + ABBV for your $10,000?
E-Monee.com, Inc develops and operates secure payment solutions that collect, manage, and disburse funds to corporate, financial, and consumer markets worldwide. It offers e-payroll program, an end-to-end electronic payroll solution that provides various financial solutions for the employer and employee; commission and vendor e-payments program, which enables companies to centralize the development of financial transactions into one mechanism; and gift/prepaid card programs. The company also provides banking financial solutions using its pre-paid processing platform that offers sales, marketing, and customer support, as well as accounts management. In addition, it offers electronic payment solutions, card issuing and processing systems, payroll solutions, virtual banking solutions, ATM solutions, point of service solutions, customer service support and solutions, fraud management and filtering solutions, and platform customization solutions. E-Monee serves maritime industry, retailers, restaurants, government agencies, convenience stores, grocery stores, pharmacies, travel, entertainment, and healthcare industries. E-Monee.com, Inc was founded in 2000 and is based in Fort Lauderdale, Florida.
Full EMNC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.